Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

IM Cannabis Corp C.IMCC

Alternate Symbol(s):  IMCC

IM Cannabis Corp. is a Canada-based international cannabis company that provides cannabis products to medical patients in Israel and Germany. The Company's ecosystem operates in Israel through its commercial relationship with Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel. In Germany, the Company operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. It offers four different product lines, leading with the Craft Collection which offers the highest quality Canadian craft cannabis flower. The Company's other product lines include Top-Shelf Collection, Signature Collection and Full Spectrum Extracts. The Company's brands include The WAGNERS, BLKMKT, LOT420, and The PICO collection (minis).


CSE:IMCC - Post by User

Comment by RockMaschineon Jun 21, 2022 11:29am
191 Views
Post# 34771319

RE:RE:RE:IMCC Managment - Stop Blaming the Market Trends!!

RE:RE:RE:IMCC Managment - Stop Blaming the Market Trends!!
It would be the entire IM Cannabis organization that would be sold. Which means Focus medical and Adjupharm, along with Panaxia and all the other pharmacies acquired. Not going to happen, the company is just one the kind who do things and don't say anything. Beyond unknown in the sector and susceptible to Nasdaq games without the size and liquidity to have attacks on share price fended off. Don't even bring up delisting until October because it will take that long for Nasdaq to pursue action. Not even at 30 days for the intial warning. And should Nasdaq listing end then it will continue on the CSE which have no such rules.
<< Previous
Bullboard Posts
Next >>